Thomas Hansen-Holst

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.

Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.

Journal: Diabetes, obesity & metabolism

Published: December 12, 2025

Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial.

Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial.

Journal: The lancet. Diabetes & endocrinology

Published: March 18, 2025

The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight Loss Intervention Studies.

The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight Loss Intervention Studies.

Journal: Advances in therapy

Published: April 12, 2024

Tipping-point transition from transient to persistent inflammation in pancreatic islets.

Tipping-point transition from transient to persistent inflammation in pancreatic islets.

Journal: NPJ systems biology and applications

Published: April 03, 2024

The association between body mass index and health-related quality of life in the 2017 and 2018 health survey of England data: A cross-sectional observational analysis.

The association between body mass index and health-related quality of life in the 2017 and 2018 health survey of England data: A cross-sectional observational analysis.

Journal: Diabetes, obesity & metabolism

Published: December 06, 2023

Treatment effect of semaglutide 2.4 mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights.

Treatment effect of semaglutide 2.4 mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights.

Journal: Diabetes, obesity & metabolism

Published: August 24, 2023

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: May 23, 2023

Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.

Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.

Journal: Obesity (Silver Spring, Md.)

Published: March 30, 2023

The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.

The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.

Journal: Diabetes, obesity & metabolism

Published: December 21, 2022

Spatiotemporal NF-κB dynamics encodes the position, amplitude, and duration of local immune inputs.

Spatiotemporal NF-κB dynamics encodes the position, amplitude, and duration of local immune inputs.

Journal: Science advances

Published: August 31, 2022

Impact of Zygosity on Bimodal Phenotype Distributions.

Impact of Zygosity on Bimodal Phenotype Distributions.

Journal: Biophysical journal

Published: November 15, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026